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New insights into the glycosylation steps in the biosynthesis of
Sch47554 and Sch47555
Ozkan Fidan†[a], Riming Yan,†[a,b] Gabrielle Gladstone,[a] Tong Zhou,[a] Du Zhu,*[b] Jixun Zhan*[a]
Abstract: Sch47554 and Sch47555 are antifungal compounds from
Streptomyces sp. SCC-2136. The availability of the biosynthetic gene
cluster made it possible to track down the genes encoding
biosynthetic enzymes responsible for the structural features of these
two angucyclines. Sugar moieties play important roles in the biological
activities
of
many
natural
products.
Investigation
of
glycosyltransferases (GTs) may potentially help diversify
pharmaceutically significant drugs through combinatorial biosynthesis.
Sequence analysis indicated that SchS7 is a putative C-GT, while
SchS9 and SchS10 were proposed to be O-GTs. In this study, we
characterized the roles of these three GTs in the biosynthesis of
Sch47554 and Sch47555. Co-expression of the aglycone and sugar
biosynthetic genes with schS7 in Streptomyces lividans K4 resulted in
the production of C-glycosylated rabelomycin, which revealed that
SchS7 attaches a D-amicetose moiety to the aglycone core structure
at the C-9 position. Gene inactivation studies revealed that
subsequent glycosylation steps take place in a sequential manner in
which SchS9 first attaches either a L-aculose or L-amicetose moiety
to the 4'-OH of the C-glycosylated aglycone, then SchS10 transfers a
L-aculose moiety to the 3-OH of the angucycline core.

Introduction
Angucycline antibiotics are a group of biologically active natural
products synthesized by type II polyketide synthase (PKS)
complexes through a sequence of reactions. [1,2] Angucyclines
exhibit diverse biological activities including antiviral (SM 196 B),
antibacterial (marangucycline A, vineomycin A1), antitumor
(landomycin A, urdamycin A, and marangucycline B) and
antifungal properties (Sch47554 (1) and Sch47555 (2), Figure
1).[3–8] Sch47554 and Sch47555 are produced by Streptomyces
sp. SCC-2136 (ATCC 55186) and exhibit antifungal activity
against various yeasts and dermatophytes. [6] The entire
biosynthetic gene cluster encoding the biosynthesis of Sch47554
and Sch47555 has been previously reported.[9] The availability of
biosynthetic gene cluster (NCBI accession number AJ628018)

[a]

[b]

[†]

made it possible to track down the genes encoding biosynthetic
enzymes responsible for the structural features of these two
angucyclines. The Sch47554 and Sch47555 (sch) biosynthetic
gene cluster includes enzymes responsible for the biosynthesis of
the core polyketide backbone (SchP6-8) and nucleotidyl-activated
sugar moieties (SchS1-6). It additionally encodes some tailoring
enzymes such as aromatase (SchP4), ketoreductase (SchP5),
cyclase (SchP9), oxygenase (SchP10), and three putative
glycosyltransferases (GTs) (SchS7, SchS9, and SchS10).[9]
GTs catalyze the transfer of activated sugar moieties to the
acceptor molecules and are commonly involved in the
biosynthesis and modification of many pharmaceutically
significant natural products.[10] Regio- and stereo-specifically
attached sugar moieties play important roles in both binding of
drugs to biological targets and biological activity of many natural
products.[11,12] For instance, landomycin A with a hexasaccharide
side chain exhibits much stronger antitumor activity compared to
its derivative, landomycin E with a trisaccharide side chain. [13] GTs
hold huge potential for helping diversify pharmaceutically
important drugs through the combination of chemoenzymatic and
in vivo methods.[14] For this purpose, heterologous expression and
in-frame gene deletion approaches have been implemented in
many studies. For example, Rodriguez et al. generated hybrid
elloramycin analogs by combinatorial biosynthesis using genes
from anthracycline-type and macrolide biosynthetic pathways. [15]
Tang and McDaniel also benefited from combinatorial
biosynthesis to produce desosaminylated macrolactones and
paved the way for the production of ‘unnatural’ natural product
libraries.[16] Trefzer et al. were able to produce novel glycosylated
urdamycin derivatives by overexpressing GT genes from
landomycin-producing strain of Streptomyces cyanogenus S136
in a mutant of urdamycin-producing strain of Streptomyces
fradiae Tü 2717.[17] With a similar strategy, Ostash et al.
generated novel landomycins in a mutant strain. [13] Künzel et al.
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Figure 1. Structures of Sch47554 (1) and Sch47555 (2).
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and Luzhetskyy et al. performed targeted gene inactivation
including the inactivation of genes encoding GTs, leading to the
formation of urdamycins I, J, K and landomycins M and O,
respectively.[18,19] All these studies indicate that novel and/or
unnatural natural products can be generated by the inactivation of
GT genes and combinatorial biosynthesis.
In the present study, we elucidated the roles of three GTs involved
in the biosynthesis of 1 and 2. We have used two aforementioned
approaches to functionally characterize GTs in the sch
biosynthetic gene cluster. The function of schS7 was
characterized through heterologous expression, while we
performed targeted gene inactivation for schS9 and schS10.
These two approaches not only revealed the function of GTs, but
also help to diversify the pharmaceutically relevant molecules
through the production of two novel compounds.

analysis revealed that a major product 3 was generated by S.
lividans K4/pOF10. through heterologous expression of schP4-10
genes (pOF10) in S. lividans K4 (Figure 2A). The ESI-MS
spectrum of 3 showed the [M+H]+ ion peak at m/z 339.0 (Figure
S4), indicating that its molecular weight is 338, which is same as
that of rabelomycin, a common intermediate in angucycline
biosynthesis. The structure of 3 was confirmed to be rabelomycin
(Figure 2B) based on a comparison of its 1H NMR data for 3 with
previously reported data.[25]

A

S. lividans K4/pRM5

3
S. lividans K4/pOKF10

Results and Discussion
Sequence analysis of the putative GTs in the sch
biosynthetic gene cluster
The sch biosynthetic gene cluster contains three putative GT
genes (schS7, schS9, and schS10). Multiple amino acid
sequence analysis of SchS7 using Clustal Omega revealed its
homology to known C-GTs: 72.33% identity with UrdGT2 from
Streptomyces fradiae, 68.78% identity with SaqGT5 from
Micromonospora sp. Tü 6368 and 55.97% identity with SimB7
from Streptomyces antibioticus Tü6040, as well as to a known OGT, LanGT2 from Streptomyces cyanogenus with 58.71% identity
[14,20–22]
. Multiple amino acid sequence analysis of SchS9 revealed
its similarity to several characterized O-GTs: 58.91% identity with
UrdGT1c from Streptomyces fradiae, 58.21% identity with
SaqGT4 from Micromonospora sp. Tü 6368, and 54.38% identity
with LanGT1 from Streptomyces cyanogenus.[17,21,23] Similarly,
multiple amino acid sequence analysis of SchS10 revealed its
homology to a few O-GTs: 54.50% identity with SaqGT2 from
Micromonospora sp. Tü6368, 49.40% identity with LanGT4 from
Streptomyces cyanogenus, and 48.82% identity with UrdGT1a
from Streptomyces fradiae.[17,21,23] Clustal Omega multiple
sequence alignments for each GTs (Figures S1-S3) indicated that
SchS7 is expected to possess the function of C-GT, whereas
SchS9 and SchS10 are predicted as O-GTs.
Functional characterization of schS7 through heterologous
expression
Based on the sequence analysis, SchS7 is predicted to be
responsible for the attachment of a sugar moiety to C-9 of the
aglycone backbone via the formation of a C-C bond. To verify the
function of this putative C-GT, we first aimed at the expression of
minimal PKS genes of sch gene cluster (schP6-8) and of oxy gene
cluster (oxyABC) to test the putative functions of SchP6, SchP7,
and SchP8, which led to the production of SEK15, same product
from the co-expression of OxyABC from the oxytetracycline
biosynthetic pathway (data not shown).[24] We then expressed
more genes in an attempt to produce a stable aglycone for GT
studies. To this end, schP4-10 genes was ligated into the pRM5
vector, an Escherichia coli/Streptomyces shuttle vector to yield
pOF10, which was then expressed in S. lividans K4. HPLC
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Figure 2. Production of rableomycin (3) and 9-D-amicetosyl-rabelomycin
(GG31, 4) in S. lividans K4 through heterologous expression. (A) HPLC
analysis (420 nm) of the products of S. lividans K4/pRM5 (upper), pOF10
(middle) and pGG31 (bottom). (B) Biosynthetic pathway of 3 and 4.

Using the same approach, we introduced more genes including
schS7 and the genes involved in the biosynthesis of activated
sugar moieties (schS1-S6 and schS8) to pOF10 to yield pGG31.
Expression of this set of genes in S. lividans K4 yielded another
major product 4, as shown in Figure 2A. The ESI-MS spectrum of
4 revealed the [M+H]+ ion peak at m/z 453.1 (Figure S4),
suggesting a molecular weight of 452. 4 is 114 mass units larger
than 3, indicated that 4 is a C-amicetosylated derivative of 3. To
elucidate the structure of 4, HR-MS analysis was conducted and
showed a [M+H]+ ion peak at m/z 453.1561, which is consistent
with C25H25O8 (cacld. 453.1505) (Figure S5). The formula of 4
revealed that it has 25 carbons, which has 6 more carbons than
3, further indicating that a D-amicetose moiety has been added.
This was supported by 1D and 2D NMR analysis (Table 1 and
Figure 3). The NMR data of 4 are similar to those of 3, except that
it has extra signals that belong to the D-amicetose moiety. The
13
C NMR spectrum showed 25 carbon signals. The chemical
shifts of C-6 (δ 152.3) and C-8 (δ 157.9) indicated that they are
hydroxylated carbons on the aromatic rings. Additionally, an
oxygenated quaternary carbon signal at δ 71.3 was assigned to
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C-3. These signals are consistent with those in rabelomycin. The
six carbon signals at δ 73.0, 33.2, 32.0, 79.2, 71.2 and 18.2, and
another hydroxylated CH signal belong to the D-amicetose moiety,
which further confirmed the presence of this sugar moiety in 4.
The HMBC correlation of the anomeric proton H-1 at δH 4.79 to C9 (δC 139.8) confirmed the linkage of the D-amicetose moiety to
the C-9 position (Figure 3). Accordingly, the structure of 4 can be
identified as 9- D-amicetosyl-rabelomycin and this compound was
named as GG31. Therefore, the function of SchS7 was identified
as a C-GT in the biosynthesis of Sch47554 and Sch47555 (Figure
2B).
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Figure 3. Selected 1H-1H COSY and HMBC correlations for 4 and 7.

Targeted gene inactivation of schS9 and schS10
Sequence analysis of SchS9 and SchS10 suggested that they are
responsible for O-glycosylations at 3-OH and 4'-OH of 1 and 2.
We inactivated both genes through homologous recombination to
generate mutants lacking corresponding O-GTs (Figure 4A).
Apramycin resistant exconjugants were obtained from intergenic
conjugation between Streptomyces sp. SCC-2136 and E. coli
ET12567 respectively harboring pRY9 and pRY10. The
confirmation of the single crossover events was performed by
PCR using vector- (RV-M and M13-47) and genome-specific
primers (Figure 4B). As illustrated in Figure 4A and 4B, the 2.2 kb
and 2.1 kb PCR products were amplified from Streptomyces sp.
SCC-2136/ΔschS9 genome, whereas Streptomyces sp. SCC2136 wild type genome did not yield these fragments. Similarly,
we amplified the 2.6 kb and 2.8 kb fragments from the genome of
Streptomyces sp. SCC-2136/ΔschS10, while we did not obtain
these expected fragments from the genome of wild type strain.
Thus, these PCR results confirmed the targeted gene inactivation
for schS9 and schS10.
Upon confirmation of gene inactivation, the positive exconjugants
are grown on YM plates supplemented with apramycin for product
analysis. HPLC analysis of the extracts of the cultures of
Streptomyces sp. SCC-2136/ΔschS9 and Streptomyces sp. SCC2136/ΔschS10 at 420 nm showed two same products (5 and 6) at
19.6 min and 26.5 min in both extracts. Streptomyces sp. SCC2136 ΔschS10 produced two additional compounds (8 and 7) at
26.1 and 32.5 min (Figure 4C). The ESI-MS spectra of 5, 6, 7, and
8 showed the [M-H]- ion peaks at m/z 373.0, 469.1, 583.1, and
579.1, respectively (Figure S6), indicating that their molecular
weights are 374, 470, 584, and 580, respectively. We purified all
these compounds for chemical structure elucidation, except 8 due
to the low titer. We confirmed the chemical structures of 5 and 6
based on the 1H NMR data as listed in Table1. We, additionally,
ran 1H, 13C, HSQC, and HMBC NMR as well as HR-MS for OZK1
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Figure 4. Gene disruption of schS9 and SchS10. (A) Single crossover
recombination strategy for disruption of schS9 (i) and SchS10 (ii) in
Streptomyces sp. SCC-2136. (B) PCR confirmation of the Streptomyces
sp. SCC-2136/ΔschS9 (i) and Streptomyces sp. SCC-2136/ΔschS10 (ii)
single crossover mutants. (i) Confirmation of the insertion of pRY09 into
the genome of Streptomyces sp. SCC-2136. M: 1 kb plus DNA ladder; 1:
primers sch9-F/M13-47 with the wild type as the template; 2: primers sch9F/M13-47 with the ΔschS9 mutant as the template; 3: primers sch9-R/RVM PCR with the wild type as the template; 4: primers sch9-R/RV-M PCR
product with the ΔschS9 mutant as the template. (ii) Confirmation of the
insertion of pRY10 into the genome of Streptomyces sp. SCC-2136. M: 1
kb plus DNA ladder; 1: primers sch10-F/M13-47 PCR with the wild type as
the template; 2: primers sch10-F/M13-47 with the ΔschS10 mutant as the
template; 3: primers sch10-R/RV-M with the wild type as the template; 4:
primers sch10-R/RV-M with the ΔschS10 mutant as the template. (C)
HPLC traces (at 420 nm) for the cultures Streptomyces sp. SCC-2136/wildtype (upper), ΔschS9 (middle) and ΔschS10 (bottom).

(7) (Table 1 and Figure 3) to elucidate its chemical structure of
this new compound. NMR data analysis for 5 and 6 confirmed the
structure of previously reported compounds of urdamycin X and
3'-deoxyaquayamycin, respectively.[6,26] Urdamycin X was
reported to be a surprising shunt product in Streptomyces
fradie/ΔurdQ/R, while 3'-deoxyaquayamycin is a common Cglycosylated intermediate compound in angucycline biosynthesis.
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Compounds 7 and 8, on the other hand, are O-glycosylated
intermediate compounds. HR-MS for 7 indicated a [M-H]- ion peak
at 583.2559, which is consistent with the calculated exact mass
of 583.2224 (Figure S7), indicating that the molecular formula of
7 is C31H36O11. This was supported by the NMR data (Table 1)
containing 31 carbon signals. The chemical shift of C-8 (δ 159.3)

indicates a hydroxyl group attached to the aromatic ring. In
addition, similar to 6, 7 contains the tertiary hydroxyl groups at the
C-4a (δ 132.1) and C-12b (δ 133.9) positions and an anomeric
hydroxyl group at C-4' position (δ 72.14). As the molecular weight
of 7 suggests, we found an additional anomeric proton signal (CH1'') at δC 98.4 and δH 4.91, indicating that 7 has one more

Table 1. 1H NMR data for 3 (in CDCl ), 4 (in (CD ) CO), 5 (in CD OD), 6 (in DMSO-d6), and 7 (in CDCl ) and 13C NMR data for 4 and 7.
3

Position

Rabelomycin
(3)

GG31
(4)

1

-

2.80 (d, 1H,
14.6)
2.95 (d, 1H,
14.6)

2

2.99 (d, 1H, 15.1)
3.07 (d, 1H, 15.1)

3

-

-

3.12 (s, 2H)

3.14 (d, 2H,
11.9)

4
4a

-

-

5

7.04 (s, 1H)

7.08 (s, 1H)

6

-

-

6a

-

-

7

-

-

7a

-

8

-

3 2

3

3

Urdamycin X
(5)

3'-Deoxyaquayamycin
(6)

OZK1
(7)

GG31 (4)[a]

OZK1
(7)[a]

-

-

-

195.1

174.4

1.95 (dd, 1H,
13.8, 3.0)
2.33 (d, 1H, 13.8)

2.35 (d, 2H, 15.0)

2.62 (d, 2H,
14.8)

53.4

44.8

-

-

71.3

72.16

2.90 (d, 1H, 13.0)
3.02 (d, 1H, 13.0)

3.08 (m, 2H)

44.0

41.2

2.20 (d, 1H, 10.5)
2.03 (dd, 1H,
10.5, 3.3 )
1.67 (m, 1H)
2.11 (m, 1H)
2.61 (td, 1H, 12.1,
3.4)
2.85 (td, 1H, 11.9,
5.6)

-

-

129.7

132.1

7.81 (d, 1H, 7.8)

7.64 (d, 1H, 7.7)

121.5

139.5

7.72 (d, 1H, 7.7)

7.82 (d, 1H, 7.7)

152.3

119.1

-

-

-

116.8

115.8

-

-

-

193.1

188.3

-

-

-

-

114.8

115.3

-

-

-

-

157.9

159.3

-

-

134.5

139.8

7.25 (dd, 1H, 6.3,

9

7.30 (d, 1H, 2.6)

-

10

7.72 (d, 1H, 4.7)

7.94 (d, 1H, 7.7)

7.59 (d, 1H, 7.7)

7.86 (d, 1H, 7.9)

7.92 (d, 1H,7.9)

134.1

133.4

11

7.70 (d, 1H, 4.8)

7.56 (d, 1H, 7.6)

7.58 (d, 1H, 7.6)

7.79 (d, 1H, 6.3)

7.85 (d, 1H, 7.9)

118.2

119.6

11a

-

-

-

-

-

138.1

131.5

12

-

-

-

-

-

182.9

188.0

12a

-

-

-

-

-

138.2

161.0

12b

-

-

-

-

-

128.6

133.9

13

1.52 (s, 3H)

1.47 (s, 3H)

1.54 (s, 3H)

1.16 (s, 3H)

1.34 (s, 3H)

29.6

27.2

73.0

73.2

1'

-

2'

-

3'

-

4'
5'

4.79 (d, 1H,

2.7)

4.85 (d, 1H,

-

4.70 (d, 1H, 10.6)

-

1.39 (m, 1H)
2.09 (m, 1H)

1.46 (m, 2H)

33.2

31.7

2.14 (m, 2H)

-

1.55 (m, 1H)
2.02 (m, 1H)

2.27 (m, 2H)

32.0

31.8

-

3.23 (m, 1H)

-

3.12 (m, 1H)

3.32 (m, 1H)

79.2

79.7

-

3.40 (m, 1H)

-

3.33 (m, 1H)

3.55 (m, 1H)

71.16

77.6

6'

-

1.33 (d, 3H, 6.0)

-

1.26 (d, 3H, 6.0)

1.35 (d, 3H, 6.1)

18.2

18.5

1''

-

-

-

-

4.91 (s, 1H)

-

98.4

2''

-

-

-

-

1.90 (m, 2H)

-

27.7

3''

-

-

-

-

1.80 (m, 2H)

-

30.5

4''

-

-

-

-

3.31 (m, 1H)

-

72.14

5''

-

-

-

-

3.76 (m, 1H)

-

69.9

6''

-

-

-

-

1.27 (d, 3H, 6.2)

-

17.8

10.8)
1.61 (m, 2H)

[a] 13

C NMR data for 4 and 7.
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amicetose sugar moiety. HBMC correlation of H-1'' to C-4'
revealed the linkage of the second amicetose moiety to 4'-OH of
6. Thus, 7 was characterized as L-amicetosyl-3'deoxyaquayamycin. All the signals are assigned according to the
1D and 2D NMR spectra (Table 1). Based on our findings, we
proposed the glycosylation steps in the biosynthesis of 1 and 2 as

illustrated in Figure 5. Glycosylation occurs in a sequential
manner in which SchS7 first C-glycosylates the polyketide
aglycone,
followed
by
the
O-glycosylation
of
3'deoxyaquayamycin by SchS9. Lastly, SchS10 attaches the third
sugar moiety to the C-3 position, leading to the production of 1
and 2.

Figure 5. Proposed glycosylation steps in the biosynthesis of 1 and 2.
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Discussion
Many natural products are produced through the assembly of their
aglycone core structure followed by the decoration with sugar
moieties. The biological activities of many natural products
including medicinally significant antibiotics and anticancer drugs
depends on the regio- and stereo-specifically attached sugar
moieties.[11,27] Chemical synthesis of sugar moieties is excessively
difficult to perform and impractical to establish in large scale.[14]
Thus, GTs are useful alternatives tools for chemoenzymatic and
in vivo approaches to develop glycosylated natural products. [27]
Many GT genes have been isolated from antibiotic-producing
microorganisms and functionally characterized mostly by gene
inactivation experiments and in a few cases by heterologous
expression. Among these GTs are lanGT1, lanGT2, lanGT3 and
lanGT4 in the landomycin gene cluster,[14,17,28,29] urdGT1a,
urdGT1b, urdGT1c and urdGT2 in the urdamycin gene
cluster,[20,23,30,31] saqGT1, saqGT2, saqGT3, saqGT4, saqGT5,
saqGT6 in the saquayamycin Z gene cluster, [21] mtmGI, mtmGII,
mtmGIII and mtmGIV in the mithraycin gene cluster,[32,33] oleG1
and oleG2 in the oleandomycin gene cluster,[34,35] and dnrS in the
daunosamine gene cluster.[36]
1 and 2 are two antifungal angucyclines that possess three sugar
moieties. However, how these sugars are added to the structures
remains unknown. The sch gene cluster contains three putative
GT genes (schS7, schS9, schS10).[9] Based on multiple sequence
comparison of the deduced amino acid sequences of GTs in the
sch biosynthetic gene cluster, SchS7 showed high homology to
several known C-GTs including UrdGT2, SaqGT5, and SimB7.
SaqGT5 attaches an activated D-olivose moiety directly to the C9 position of angucycline in the case of saquayamycin Z and of
tetracenequinone in the case of galtamycin B.[21] SimB7 and
UrdGT2 are also responsible for the attachment of an activated
D-olivose to C-9 of polyketide aglycone.[22,31] In particular, UrdGT2
attaches an activated D-olivose to C-9 of 2-hydro-3-hydroxyprejadomycin (UWM6) or terangulol.[14,31] The examples of
SaqGT5 and UrdGT2 show the substrate flexibility that will
facilitate the synthesis of derivative compounds using those CGTs. UrdGT2 also functions as O-GT and transfers the activated
D-olivose sugar moiety to 1,2-dihydroxyanthraquinone.[20]
Surprisingly, multiple sequence comparison also revealed high
homology of SchS7 to a known O-GT, LanGT2 from
Streptomyces cyanogenus which catalyzes the first glycosylation
step by attaching activated D-olivose to 8-OH of the aglycone.[14]
Interestingly, an engineered version of LanGT2 was able to act as
C-GT, showing activity for both C- and O-glycosylation similar to
UrdGT2.[20,37] Therefore, we expected SchS7 to be responsible for
the attachment of D-amicetose to C-9 of the polyketide aglycone.
To characterize its function, we have used a heterologous
expression approach to create two expression plasmids, pOF10
and pGG31. pOF10 contains the minimal PKS genes (schP6,
schP7, and schP8) and aromatase, ketoreductase, cyclase, as
well as oxygenase genes (schP4, schP5, schP9, and schP10),
while pGG31 additionally includes schS7 and genes required for
the biosynthesis of activated sugar moieties (schS1, schS2,
schS3, schS4, schS5, schS6, and schS8). S. lividans K4
harboring pOF10 and pGG31 respectively produced two major
peaks of rabelomycin (3) and a novel compound, D-amicetosylrabelomycin (4), proving that SchS7 is responsible for the

attachment of a D-amicetose sugar moiety to the C-9 position of
3.
Sequence analysis of SchS9 and SchS10 revealed that are
homologous to known O-GTs such as UrdGT1a, UrdGT1c,
SaqGT2, SaqGT4, LanGT1, and LanGT4. In particular, SchS9 is
highly homologous to SaqGT4 and UrdGT1c which attach
activated L-rhodinose to the first sugar moiety in the biosynthesis
of saquayamycin Z and urdamycin A, respectively. UrdGT1c
transfers a L-rhodinose sugar moiety to urdamycinone B, 100-2,
and aquayamycin at 3'-OH, while SaqGT4 attaches the third and
fifth sugar moieties at 3-OH of the saccharide chain.[21,23] This
indicates the substrate flexibility of these enzymes and SchS9
might potentially recognize different substrates. Additionally,
SchS9 has high homology to LanGT1 from the landomycin
biosynthetic gene cluster that is responsible for the attachment of
D-olivose to 4'-OH of the first sugar moiety.[17] For SchS10,
multiple sequence alignment showed that it is highly homologous
to SaqGT2 and UrdGT1a that are responsible for the attachment
of L-rhodinose at 12b-OH and 3-OH, respectively.[21,23] The amino
acid sequence of SchS10 is also similar to that of LanGT4 which,
in contrast to SaqGT2 and UrdGT1a, attaches the third sugar
moiety (L-rhodinose) to the saccharide chain at C-9.[17] Therefore,
both SchS9 and SchS10 are expected to catalyze the Oglycosylation steps in Sch47554 and Sch47555 biosynthesis. To
confirm their function, we disrupted the corresponding genes
through targeted gene deletion. HPLC analysis of the extracts of
Streptomyces sp. SCC-2136/ΔschS9 and Streptomyces sp. SCC2136/ΔschS10 mutants revealed that both mutants produced 5
and 6 in common. Streptomyces sp. SCC-2136/ΔschS10
produced two additional compounds (7 and 8) (Figure 4C). Except
8 which was only characterized with LC-MS due to the very low
titer, all compounds were purified and characterized by LC-MS
and NMR. Production of these compounds in the mutant strains
indicates that O-glycosylation takes place in a sequential manner
in which SchS9 first attaches either L-amicetose or L-aculose
moiety to 4'-OH of 6, then SchS10 transfers a L-aculose moiety
to 3-OH of 7 or 8 to yield 1 and 2. SchS9 has relatively relaxed
substrate specificity toward sugar donors as shown by its ability
to attach two different sugar moieties, while SchS10 is flexible
with sugar acceptors and can recognize both 7 and 8 as substrate.
8 might be a more favorable substrate for SchS10 than 7 due to
a higher titer of 1 compared to 2 in the wild type, whereas more
efficient production of 7 than 8 in Streptomyces sp. SCC2136/ΔschS10 mutant indicates that SchS9 favorably attaches an
activated L-amicetose moiety to 4'-OH of 6. Additionally, having 6
in both Streptomyces sp. SCC-2136/ΔschS9 and ΔschS10
extracts suggests that SchS7 is the dedicated C-GT that
catalyzes the first glycosylation with 9-deolivosyl aquayamycin as
the sugar acceptor substrate. 3 and 4 were not detected in the
wild type and mutant strains of Streptomyces sp. SCC-2136. The
enzymes that are involved in the 6-reduction, 5,6-dehydration and
12-oxygenation may not recognize a glycoside substrate such as
4. Production of 4 through heterologous expression in S. lividans
indicated that SchS7 has relaxed specificity towards the sugar
acceptors.
In addition, both mutant strains produced urdamycin X (5) which
was reported as a shunt product. Similar to 5, urdamycin L was
detected in a urdM mutant of S. fradie during Baeyer-Villiger
monooxygenation process in urdamycin A biosynthesis. [25] 5 is
different from urdamycin L due to the almost saturated ring B
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(additional OH groups at C-4a and C-12b), whereas urdamycin L
possesses a phenolic arene ring B with an OH group at C-6
(Figure 5).[26] However, both compounds are related to each other
by having an unusual ε-lactone as ring A. Urdamycin L is derived
from Baeyer-Villiger monooxygenation reaction through
spontaneous oxidation, while 5 is an over-oxidized analogue of
urdamycin L.[25,26] In the sch biosynthetic gene cluster, there exist
oxygenases such as schP3 and schP10 with high homology to
urdM (64%) and urdE (84%), respectively. These enzymes might
be in the oxygenation of the angucycline ring. It is surprising that
5, as a shunt product, was produced in larger quantities than the
biosynthetic intermediate 6 in the schS9 and schS10 disruption
mutants (Figure 4C). Because schS7 is located downstream of
schS9 and schS10, there is a possibility that a polar effect
occurred when the disruption plasmids were inserted into the
genome. This polar effect may cause a low level expression of the
C-GT SchS7 and thus the overall attenuation of the biosynthetic
route of 6, which in turn led to the increased accumulation of 5.

Conclusions
We used two different approaches to characterize the function of
three GTs in sch biosynthetic gene cluster; heterologous
expression for SchS7 and targeted gene disruption for SchS9 and
SchS10. As expected from multiple sequence analysis of these
GTs with their homologues, we found that the glycosylation
process in the biosynthesis of Sch47554 and Sch47555 occurs in
a sequential manner. First, SchS7, which is C-GT, attaches a Damicetose moiety to polyketide aglycone followed by the
attachment of the second sugar moiety to 4'-OH of the first sugar
moiety by SchS9. In the last step, SchS10 transfers an L-aculose
to C-3 of glycosylated polyketide aglycone, leading to the
biosynthesis of major products of Sch47554 and Sch47555. We
isolated two novel compounds, GG31 and OZK1 from these two
different
approaches,
respectively,
diversifying
the
pharmaceutically relevant compounds. With elucidating the
function of three GTs, we may combine them with other GTs to
change the saccharide chain that possibly enhances the
antifungal activity as well as diversify further the pharmaceutically
relevant antifungal compounds.

Experimental Section
Bacterial strains, media and culture conditions
Streptomyces lividans K4 strains harboring pOF10 and pGG31 were
maintained on R5 agar plates supplemented with thiostrepton at 28 C for
10 days. Streptomyces sp. SCC-2136/ΔschS9 and Streptomyces sp.
SCC-2136/ΔschS10 mutants were grown on YM agar plates
supplemented with apramycin at 28 C for 10 days. Streptomyces sp.
SCC-2136 was grown in YM broth for 5 days for genomic DNA extraction.
E. coli XL1-Blue and ET12567, which were grown in LB media at 37 C
overnight, were used for general genetic manipulations and intergenic
conjugation, respectively. MS and ISP4 media were used for conjugation
and single crossover homologous recombination, respectively. Apramycin
(50 μg/mL), thiostrepton (50 μg/mL), chloramphenicol (25 μg/mL),
ampicillin (50 μg/mL) and nalidixic acid (25 μg/mL) were supplemented
when appropriate.

General genetic manipulation and PCR
Standard molecular biology protocols were performed as previously
described.[38] Genomic DNA of Streptomyces sp. SCC-2136 and its
mutants were extracted by ZR Fungal/Bacterial DNA Miniprep Kit (Irvine,
CA, USA). Plasmid DNA extraction from E. coli cells was performed using
Thermo Scientific GeneJET Plasmid Miniprep Kit (Logan, UT, USA). PCR
reactions were performed with Arktik™ Thermal Cycler (Thermo Scientific)
using Phusion DNA polymerase (Thermo Scientific, Logan, UT, USA).
Oligonucleotide primers were ordered from Sigma-Aldrich and dissolved
in TE buffer to the concentration of 100 ng/mL.
Construction of plasmids for heterologous expression and gene
disruption
For the heterologous expression approach, schP4, schP5, schP6, schP7,
schP8, schP9 and schP10 genes were PCR-amplified from Streptomyces
sp. SCC-2136 genomic DNA using oligonucleotide primers listed in Table
S1. Specific forward and reverse primers contain compatible restriction
enzymes such as XbaI, SpeI, and NheI. The PCR products were first
ligated into the pJET1.2 cloning vector for DNA sequencing using the
Sanger method (Eton Bioscience, San Diego, CA, USA). Each
combination of genes was then constructed by the subsequent addition of
individual genes into the cloning vector and the correct ligation was
confirmed by restriction enzyme digestions. Additionally, each group of
genes was ligated into a pRM5-derived vector. The gene cassette
containing schP6, schP7, and schP8 was excised from pOF1 by using
PacI and NheI and ligated into pRM5 between the same sites to yield pOF3.
Subsequently, schP5 gene was excised from pOF2 using NheI and SpeI
and ligated into pOF3 between the same sites to yield pOF4. schP4, schP9
and schP10 were also excised from pOF5-7 and inserted in the same
sequential manner to yield pOF8-10, respectively. Similarly, schS1, schS2,
schS3, schS4, schS5, schS6, schS7 and schS8 were PCR-amplified from
the genomic DNA of Streptomyces sp. SCC-2136 and subsequently
inserted into pJET1.2 to yield pKN57. The gene cassette containing these
genes was excised from pKN57 using the NheI and SpeI restriction sites
and ligated into pOF10 digested with the same restriction enzymes to yield
pGG31. pOF10 and pGG31 plasmids were introduced into Streptomyces
lividans K4 through PEG-mediated protoplast transformation for product
analysis.
For the targeted gene disruption approach, a 672 bp fragment of schS9
and a 763 bp fragment of schS10 were PCR-amplified from the genomic
DNA of Streptomyces sp. SCC-2136 using the primers listed in Table S1.
The PCR products for schS9 and schS10 were first ligated into the
pJET1.2 cloning vector using T4 DNA ligase (New England Biolabs) to
yield pRY7 and pRY8, respectively. These plasmids were sequenced to
ensure that the genes were correct and free of mutations. The inserts were
excised from pRY7 and pRY8 with XbaI and HindIII (New England Biolabs)
and ligated to the thermal sensitive plasmid pKC1139 between the same
sites to yield pRY9 and pRY10, respectively, which were subsequently
used for gene inactivation of schS9 and schS10 in Streptomyces sp. SCC2136 through intergenic conjugation using E. coli ET12567. Positive
exconjugants for Streptomyces sp. SCC-2136/ΔschS9 and ΔschS10
mutants were transferred to ISP4 plates supplemented with apramycin and
NC, and incubated at 37 C for about 10 days to allow the plasmid to
integrate into the genome and yield the single crossover mutants. The
positive mutants were shuttled back and forth to YM and ISP4 plates
supplemented with apramycin for two generations to guarantee the
positive mutants. Positive exconjugants after genome integration were
subjected to product analysis and PCR confirmation of gene knockouts
using primers listed in Table S1. The details of PEG-mediated protoplast
transformation and intergenic conjugation protocols are described in
literature.[39]
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Production,
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extraction,

purification

and

characterization

of

S. lividans K4 harboring pOF10 and pGG31, and Streptomyces sp. SCC2136/ΔschS9 and Streptomyces sp. SCC-2136/ΔschS10 mutants were
grown for 10 days at 28 C on R5 and YM agar plates supplemented with
appropriate antibiotics, respectively. The cultures were chopped and
extracted with a mixture of solvent consisting of 89% ethyl acetate, 10%
methanol, and 1% acetic acid (v/v). The resulting extracts were dried in
vacuo, and the residues were redissolved in methanol for LC-MS analysis.
All crude extracts were separated on a silica gel 60 column using different
ratios of chloroform–methanol. The fractions with target compounds were
further separated by HPLC with an Agilent Eclipse XDB-C18 column (5 μm,
250 mm × 4.6 mm). Low-resolution ESI-MS spectra were obtained on an
Agilent 6130 LC-MS. Waters GCT high resolution mass spectrometer, with
EI/CI and LIFDI capabilities (University of California, Riverside) was used
to obtain the accurate mass spectra for the new compounds. 1D and 2D
NMR spectra were recorded on a JEOL ECX-300 or a Bruker AvanceIII
HD Ascend-500 NMR instrument. The chemical shift (δ) values and
coupling constants (J values) are reported in parts per million (ppm) and
hertz (Hz), respectively.
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The roles of three glycosyltransferases in the biosynthesis of Sch47554 and
Sch47555 in Streptomyces sp. SCC-2136 were characterized. SchS7 is a Cglycosyltransferase that attaches a D-amicetose moiety to the aglycone core
structure at the C-9 position. SchS9 then attaches either a L-aculose or Lamicetose moiety to the 4'-OH of the C-glycosylated aglycone, and SchS10 finally
transfers a L-aculose moiety to the 3-OH of the angucycline core.
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